Astec Lifesciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Astec Lifesciences Ltd reported a 28.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 34.0%.
• Its expenses for the quarter were up by 21.6% QoQ and 24.4% YoY.
• The net profit decreased 50.6% QoQ and decreased 51.8% YoY.
• The earnings per share (EPS) of Astec Lifesciences Ltd declined at 3.48 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Astec Lifesciences Ltd operates within the agrochemical industry, specializing in the production of active ingredients, intermediates, and formulations. The company is known for its expertise in the development of fungicides, herbicides, and insecticides, catering primarily to agricultural needs. As part of a larger conglomerate, Astec is positioned to leverage its technological capabilities and market access to build a robust portfolio of agrochemical products. Recent developments in the industry include an increased focus on sustainable agricultural practices and the adoption of newer technologies to improve crop yields, although specific recent company developments are not detailed in the data provided.

Revenue

For the fourth quarter of fiscal year 2026 (Q4FY26), Astec Lifesciences Ltd reported a total income of ₹161.26 crores, marking a significant increase of 28.5% from the previous quarter (Q3FY26), where total income was ₹125.54 crores. Comparatively, there was a year-over-year (YoY) growth of 34.0% when measured against the total income of ₹120.32 crores in the fourth quarter of fiscal year 2025 (Q4FY25). This growth pattern indicates an upward trajectory in revenue generation over both the quarter and the year.

Profitability

Astec Lifesciences Ltd's financial data for Q4FY26 shows a marked reduction in losses. The company registered a loss before tax of ₹7.90 crores, which is a significant improvement from the loss of ₹15.68 crores in Q3FY26, representing a quarter-over-quarter (QoQ) improvement of 49.6%. Year-over-year (YoY), the loss before tax also improved by 49.6% from the ₹15.66 crores loss recorded in Q4FY25. Profit after tax followed a similar trend, with a loss of ₹7.75 crores in Q4FY26 compared to losses of ₹15.69 crores in Q3FY26 and ₹16.08 crores in Q4FY25, reflecting respective QoQ and YoY improvements of 50.6% and 51.8%.

Operating Metrics

The company's operating metrics, notably the Earnings Per Share (EPS), illustrate a reduction in loss per share. In Q4FY26, EPS was reported at ₹-3.48, compared to ₹-7.04 in Q3FY26, showing a QoQ improvement of 50.6%. In comparison to Q4FY25, where EPS was ₹-8.20, there was a YoY improvement of 57.6%. These figures demonstrate Astec Lifesciences Ltd's progress in reducing per-share losses, both quarterly and annually. The tax component also showed a significant change, with a tax credit of ₹-0.15 crores in Q4FY26 compared to a negligible tax expense in Q3FY26 and a tax of ₹0.42 crores in Q4FY25, which translated into a substantial percentage change YoY and QoQ.